Literature DB >> 20211191

Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Yanqi Liang1, Mona Boules, Zhimin Li, Katrina Williams, Tomofumi Miura, Alfredo Oliveros, Elliott Richelson.   

Abstract

Neurotensin (NT) is a tridecapeptide that acts as a neuromodulator in the central nervous system mainly through two NT receptors, NTS1 and NTS2. The functional-anatomical interactions between NT, the mesotelencephalic dopamine system, and structures targeted by dopaminergic projections have been studied. The present study was conducted to determine the effects of NT receptor subtypes on dopaminergic function with the use of mice lacking either NTS1 (NTS1(-/-)) or NTS2 (NTS2(-/-)). Basal and amphetamine-stimulated locomotor activity was determined. In vivo microdialysis in freely moving mice, coupled with HPLC-ECD, was used to detect basal and d-amphetamine-stimulated striatal extracellular dopamine levels. In vitro radioligand binding and synaptosomal uptake assays for the dopamine transporters were conducted to test for the expression and function of the striatal pre-synaptic dopamine transporter. NTS1(-/-) and NTS2(-/-) mice had higher baseline locomotor activity and higher basal extracellular dopamine levels in striatum. NTS1(-/-) mice showed higher locomotor activity and exaggerated dopamine release in response to d-amphetamine. Both NTS1(-/-) and NTS2(-/-) mice exhibited lower dopamine D(1) receptor mRNA expression in the striatum relative to wild type mice. Dopamine transporter binding and dopamine reuptake in striatum were not altered. Therefore, lack of either NTS1 or NTS2 alters the dopaminergic system. The possibility that the dysregulation of dopamine transmission might stem from a deficiency in glutamate neurotransmission is discussed. The data strengthen the hypothesis that NT receptors are involved in the pathogenesis of schizophrenia and provide a potential model for the biochemical changes of the disease. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211191      PMCID: PMC2867664          DOI: 10.1016/j.neuropharm.2010.02.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  64 in total

Review 1.  Neurotransmitter interactions in schizophrenia--therapeutic implications.

Authors:  A Carlsson; N Waters; M L Carlsson
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

2.  Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors.

Authors:  Philippe Sarret; Michael J Esdaile; Amélie Perron; Jean Martinez; Thomas Stroh; Alain Beaudet
Journal:  J Neurosci       Date:  2005-09-07       Impact factor: 6.167

3.  Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.

Authors:  Bart N M van Berckel; Lawrence S Kegeles; Rikki Waterhouse; Ningning Guo; Dah-Ren Hwang; Yiyun Huang; Rajesh Narendran; Ronald Van Heertum; Marc Laruelle
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

4.  Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.

Authors:  B Cusack; M Boules; B M Tyler; A Fauq; D J McCormick; E Richelson
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

5.  Neurotensin-deficient mice show altered responses to antipsychotic drugs.

Authors:  P R Dobner; J Fadel; N Deitemeyer; R E Carraway; A Y Deutch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

6.  In vivo measurement of the vesicular monoamine transporter in schizophrenia.

Authors:  S F Taylor; R A Koeppe; R Tandon; J K Zubieta; K A Frey
Journal:  Neuropsychopharmacology       Date:  2000-12       Impact factor: 7.853

7.  Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons.

Authors:  J K Seamans; N Gorelova; D Durstewitz; C R Yang
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

8.  Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.

Authors:  Becky Kinkead; Paul R Dobner; Vasili Egnatashvili; Tiesha Murray; Nancy Deitemeyer; Charles B Nemeroff
Journal:  J Pharmacol Exp Ther       Date:  2005-06-29       Impact factor: 4.030

9.  Sensorimotor gating in neurotensin-1 receptor null mice.

Authors:  D Feifel; Z Pang; P D Shilling; G Melendez; R Schreiber; D Button
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

10.  Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.

Authors:  Jordan A Mechanic; Janette E Sutton; Amy E Berson; Xiaosu Wu; Joyce Kwan; Rudy Schreiber; Zhen Pang; Donald C Button
Journal:  Eur Neuropsychopharmacol       Date:  2009-02-14       Impact factor: 4.600

View more
  24 in total

1.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

2.  Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2.

Authors:  Moonnoh R Lee; David J Hinton; Sencan S Unal; Elliott Richelson; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

3.  Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine.

Authors:  F Scott Hall; Marjorie Centeno; Maria T G Perona; Jordan Adair; Paul R Dobner; George R Uhl
Journal:  Psychopharmacology (Berl)       Date:  2011-07-01       Impact factor: 4.530

4.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

Review 5.  Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.

Authors:  Laura E Schroeder; Gina M Leinninger
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-27       Impact factor: 5.187

6.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

7.  Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity.

Authors:  Darren Opland; Amy Sutton; Hillary Woodworth; Juliette Brown; Raluca Bugescu; Adriana Garcia; Lyndsay Christensen; Christopher Rhodes; Martin Myers; Gina Leinninger
Journal:  Mol Metab       Date:  2013-08-07       Impact factor: 7.422

8.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

9.  Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Jingying Li; Yuan Wang; Xiaofeng Zhao; Qiu Jin; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-03-13       Impact factor: 3.444

10.  Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat.

Authors:  Glen R Hanson; Amanda J Hoonakker; Christina M Robson; Lisa M McFadden; Paul S Frankel; Mario E Alburges
Journal:  J Pharmacol Exp Ther       Date:  2013-05-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.